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ABSTRAK (BAHASA MALAYSIA) 
 
Topik :  
PERBANDINGAN PEMBEDAHAN BERPANDUKAN “FLOURESCENCE” DENGAN 
PEMBEDAHAN KONVENSIONAL DALAM MERAWAT “GLIOMA” PERINGKAT 
TINGGI : KAJIAN PERBANDINGAN KEBERKESANAN PUSAT UTAMA DALAM 
TEMPOH 7 TAHUN 
 
Latar Belakang: 
Gred tinggi “glioma” adalah ketumbuhan otak jenis invasif dan agresif yang membawa 
“prognosis” teruk. Meskipun strategi therapeutik yang mengubati gred tinggi “glioma” 
telah berkembang dengan laju, Malaysia masih gagal mencapai rawatan yang standard 
berdasarkan panduan “National Comprehensive Cancer Network”, iaitu  “resection” 
ketumbuhan yang maksimum serta rawatan kemoterapi dan radioterapi.  Walaupun “gross 
total resection” berjaya memanjangkan jangka hayat pesakit, tetapi ianya kekal sebagai 
cabaran yang serius bagi pakar bedah otak disebabkan oleh kesukaran untuk membezakan 
sempadan ketumbuhan daripada tissue otak yang biasa. Hospital Sungai Buloh adalah 
hospital kerajaan di Malaysia yang pertama sekali dalam melaksanakan pembedahan 
Flourscence berpandu dalam rawatan gred tinggi “glioma” semenjak tahun 2010.  
 
Objektif 
Tujuan penyelidikan ini adalah untuk menganalisa kesan rawatan ketumbuhan otak dalam 
hasil ikhtiar hidup dan taraf kerja pesakit melalui pembedahan berpandukan “Flourescence” 
xvi 
 
berbanding dengan pembedahan konvensional. Kami akan mengkaji factor-factor penting 
yang mempengaruhi ikhtiar hidup semua pesakit yang mempunyai gred tinggi “glioma”. Di 
samping itu, kami juga mengenal-pasti kesan tahap “resection” terhadap taraf kerja dan  
ikhtiar hidup pesakit.  
 
Kaedah kajian 
Ini adalah kajian permerhatian retrospektif. Sejumlah 74 pesakit gred tinggi “glioma” baru 
yang menyertai kajian ini adalah mereka yang menjalani pembedahan dari 1st Januari 2008 
sehingga 31st Disember 2014. 37 pesakit yang menjalani pembedahan berpandukan 
“Flourescence” dari Januari 2010 sehingga 31st Disember 2014  dan memenuhi “inclusion” 
kriteria yang ditentukan akan menyertai dalam kajian ini. 37 pesakit dari kumpulan 
perbandingan adalah mereka yang menjalani pembedahan konvensional dari Januari 2008 
sehingga 31st Disember 2014. Pesakit akan diberi tarikh temujanji di klinik kepakaran saraf 
otak sebelum balik rumah (kebanyakan adalah 6 miggu dan 6 bulan dari tarikh 
pembedahan). Pesakit yang tidak layak terlibat dalam  kajian ini adalah umur kurang 
daripada 18 tahun atau melebihi 65 tahun, wanita hamil, status fungsi kehidupann “KPS” 
sebelum pembedahan < 70,   lebih dari satu ketumbuhan di otak, kedudukan ketumbuhan 
yang dalam and susah dibuangkan, ketumbuhan di bahagian tubuh badan yang lain sebelum 
ini dan pernah menerima rawatan.  Semua maklumat pesakit yang diperolehi melalui rekod 
perubatan elektronik akan dianalisa dengan menggunakan “Statistical Package for Social 
Sciences” versi 22.0. Min dan tahap ralat dikira bagi nilai berterusan, frekuensi dan 
peratusan bagi nilar kategori.  Ujian “Pearson Chi-square” digunakan untuk nilai kategori 
bandingan antara dua kumpulan. Sekiranya nilai jangkaan frekuensi kurang dari lima bagi 
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dua puluh peratus sel, maka Ujian Fisher Exact akan digunakan. Jangka hidup pesakit yang 
dikira dari tarikh pesakit menjalani pembedahan sehingga pesakit meninggal atau tempoh 
tamat penyelidikan akan dianalisa dengan kaedah “Kaplan Meir”. Faktor-faktor peramal 
hidup pesakit akan ditentukan dengan menggunakan model “Cox Proportional Hazards 
Regression”. Nilai nyata ditentukan pada nilai p kurang dari 0.05. 
 
Keputusan 
Seramai tujuh puluh empat pesakit gred tinggi “glioma” telah menjalani pebedahan di 
Hospital Sungai Buloh antara Januari 2008  dan 21st Disember 2014. pesakit yang 
menjalani pembedahan berpandukan “Flourescence” hidup lebih lama berbanding dengn 
pesakit yang menjalani pembedahan konvensional, iaitu 12 bulan berbanding dengan 8 
bulan (p < 0.02). Tanpa rawatan kemoterapi dan radioterapi, pesakit dari kumpulan 
“Flourescence” hidup selama 8 bulan berbanding dengn pesakit kumpulan konvensional 
yang cuma hidup selama 3 bulan (p = 0.006). Tiada perbezaan dari segi taraf kerja antara 
dua kumpulan setelah 6 minggu dan 6 bulan pembedahan dijalanan. Anallisa berkaitan 
dengan faktor-faktor yang nyata secara statistik yang mempngaruhi hasil ikhtiar hidup 
pesakit termasuk status fungsi kehidupan sebelum permbedahan yang melebihi 80 (p = 
0.01), kaedah pembedahan (p = 0.001), gred “glioma” (p = 0.001) dan rawatan kemoterapi 
dan radioterapi (p = 0.001). Analisa berkaitan dengan faktor-faktor yang nyata secara 
statistik yang mempngaruhi hasil ikhtiar hidup pesakit melalui “multiple logistic 
regression” termasuk ketumbuhan di lokasi “ non-eloquent/ near eloquent” (p=0.092), 
kaedah pembedahan (p = 00.087) dan rawatan kemoterapi dan radioterapi (p = 0.094).  
Walaupun, kesan tahap “resection” tidak mencapai statistikk yang nyata, pesakit yang 
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mempunyai tahap “resection”  ketumbuhan yang melebihi 90% hidup selama 10 bulan, 
iaitu 2 bulan lebih panjang berbanding dengan pesakit yang cuma mencapai tahap 
“resection” yang kurang dari 90%. 
 
Rumusan 
Penyelidikan in menunjukan pesakit mendapat manfaat lebih dari segi hasil ikhtiar hidup  
sekiranya menjalani pembedahan berpandukan “Flourescence” berbanding pembedahan 
konveksi tanpa menyebabkan kesan buruk terhadap taraf kerja pesakit. 4 faktor nyata yang 
mempengaruhi hasil ikhtiar hidup pesakit  telah dikenapasti. Tetapi, cuma 3 factor nyta 
yang mempengaruhi hasil ikhtiar hidup pesakit  telah dikenapasti melalui “multiple logistic 
regression” analisa. Kesan tahap “resection” tidak mencapai statistik yang nyata disebabkan 
oleh cuma segolongan  kecil pesakit dari kumpulan “Flourescence” yang  dapat menjalani 
pengimejan “MRI” kepala setelah pembedahan. Kita berharap hasil dari penyelidikan boleh 
dijadikan rujukan dan mencetuskan minat penyelidik untuk menjalani penyelidikan yang 
melibatkan lebih banyak pesakit terutama “multi-centered randomized trials” bagi tujuan 
mempekukuhkan kesimpulan penyelidikan ini . Kita juga menyaran supaya pusat 
neurosurgical yang lain di Malaysia juga melaksanakan penggunaan “adjunct: 5-ALA” 
dalam merawat pesakit yang mempunyai ketumbuhan otak gred tinggi  dan memanfaatkan 
lebih banyak pesakit.  
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ABSTRACT (ENGLISH) 
 
Title 
FLUORESCENCE GUIDED VERSUS CONVENTOINAL SURGICAL RESECTION OF 
HIGH GRADE GLIOMA: A SINGLE CENTRE 7 YEAR COMPARATIVE 
EFFECTIVENESS STUDY 
  
Background 
High grade gliomas (HGGs) are locally invasive and aggressive brain tumors that carry 
dismal prognosis.  Despite the rapidly evolving therapeutic strategies to treat HGGs, 
Malaysia still failed to demonstrate the expected standard HGGs management. According 
to National Comprehensive Cancer Network (NCCN) Guideline, the current standard 
management of HGGs includes maximum safe microsurgery resection followed by 
chemotherapy and radiotherapy. Complete resection, though increases median survival, is 
often hindered by the challenge of demonstrating the tumor border reliably. Department of 
Neurosurgery Hospital Sungai Buloh therefore has adopted fluorescence guided (FG) 
surgery using 5-aminolevulinic acid (5-ALA) as the first public hospital in Malaysia to 
overcome this shortcoming since 2010.   
 
Objectives 
The aim of this research was to evaluate the effects of fluorescence guided (FG) surgery on 
overall survival and functional outcome as compared to conventional surgery. Besides, the 
study also aimed to find out the independent predictors that are associated with survival in 
xx 
 
high grade gliomas (HGGs) patients. Lastly, the effect of the extent of surgical resection on 
overall survival and functional outcome in FG patients was also evaluated.  
 
Methodology 
This study was a retrospective observational study. 74 patients with histologically proven 
high grade gliomas (HGGs) were recruited between January 2008 and December 2014. 37 
HGG patients that underwent FG surgery from January 2010 until 31st December 2014 and 
fulfilled the inclusion criteria were recruited.  Another 37 patients from conventional group 
was recruited consecutively from January 2008 until 31st December 2014 as the comparison 
group. The follow-up periods were done according to the scheduled appointment date 
(mostly at 6 weeks and 6 months) from the date of operation, which ended on 30rd June 
2015.  Patients, who were below 18 years old and above 65 years old, preoperative KPS 
<70, recurrent multicentric, midline deep seated tumor, history of malignant tumor at other 
body site, known and suspected pregnancy were excluded in the study. Data entry and 
analysis was done using Statistical Package for Social Sciences (SPSS) version 22.0. Mean 
and standard deviation were calculated for continuous variables, and frequency and 
percentage for categorical variables. Pearson Chi-square were identified, however if 
expected frequency of less than five were more than twenty percent of cells, Fischer’s 
Exact Test was applied. Patient’s cumulative life span following the date of surgery at our 
institution were analyzed using Kaplan Meier method and the evaluation of difference 
survival existence between groups through log rank test The prognostic factors for 
predictor of survival in high grade glioma patients were determine using Cox Proportional 
Hazards Regression Model. The significant value was set at p value less than 0.05.  
xxi 
 
Results 
Seventy four High grade glioma patients treated in Hospital Sungai Buloh between January 
2008 and 31st December 2014 were studied. Significant survival advantage was observed in 
fluorescence guided group compared with conventional group (12 versus 8 months), p<0.02.   
Even without adjuvant therapy, HGG patients from FG group survived longer than those 
from conventional group with a documented median survival of 8.0 months versus 3 
months (p = 0.006). No significant differences of postoperative Karnofsky performance 
scale (KPS) between groups. At 6 week and 6 months postoperative, FG patients in the 
study did not succumb into worsening of functional outcome as compared to conventional 
group. Patient in both group also showed better KPS scores in the short term and long term 
follow up period.  Multivariate analysis identified four independent predictors of survival: 
KPS>80 (p=0.01), histology (p<0.001), surgical method (p<0.001) and adjuvant therapy 
(p<0.001). Multiple logistic regression analysis showed only three predictors of survival: 
tumor located in non-eloquent or near eloquent area (p=0.092), surgical method (0.087) and 
adjuvant therapy (0.094). Although FG patients did not demonstrate significant influence of 
extent of surgical resection on patients’ survival and functional outcome, patients with 
GTR/ NTR appeared to survive longer than STR (10.0 months vs 8.0 months).  
 
Conclusions 
This study showed a significant clinical benefit for HGG patients in terms of overall 
survival using FG surgery without resulting in worsening of postoperative function 
outcome when compared with conventional surgical method. Besides, four independent 
predictors of survival were also identified using multivariate analysis in the present study: 
xxii 
 
Karnofsky performance scale (KPS), tumor grade, surgical method and adjuvant therapy. 
Whereas, the predictor of survival in multiple logistic regression analysis only include 
tumor located in non-eloquent area, surgical method and adjuvant radio-chemotherapy. 
Even though, we were unable to establish a statistically significant finding in term of the 
effect of extent of surgical resection, the results obtained could be due to a limited number 
of patients that had early postoperative magnetic resonance imaging (MRI). This we hope 
will generate interest among future researchers to carry out multi-centered randomized 
trials which can analyze larger amounts of patients to further draw a concrete conclusion to 
support our claim. We hope that this surgical method can be introduced to other public 
hospital in Malaysia thus improve the clinical outcome of high grade glioma (HGG) 
patients.  
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STUDY 
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Degree of Master of Surgery (Neurosurgery) 
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Health Campus, 16150 Kelantan, Malaysia 
 
 Introduction: High grade gliomas (HGGs) are locally invasive brain tumors that carry 
dismal prognosis. According to National Comprehensive Cancer Network (NCCN) Guideline, 
the current standard management of HGGs includes maximum safe microsurgery resection 
followed by chemotherapy and radiotherapy. Although complete resection increases median 
survival, difficulty to demonstrate the tumor border reliably intraoperatively is a norm. 
Department of Neurosurgery Hospital Sungai Buloh has adopted fluorescence guided (FG) 
surgery using 5-aminolevulinic acid (5-ALA) as the first public hospital in Malaysia to overcome 
this shortcoming. 
 
 Objectives: The aims of this study were to evaluate the effect of FG surgery on overall 
survival and functional outcome as compared to conventional surgery. It also aimed to identify 
the significant independent predictors of survival in HGGs patients. Lastly, the effect of the 
extent of surgical resection on overall survival and functional outcome in FG patients was also 
evaluated. 
 
 Patients and Methods: This study was a retrospective observational study. 74 patients 
with histologically proven high grade gliomas (HGGs) were recruited between January 2008 and 
December 2014. 37 HGG patients that underwent FG surgery from January 2010 until 31st 
December 2014 and fulfilled the inclusion criteria were recruited.  Another 37 patients from 
conventional group was recruited consecutively from January 2008 until 31st December 2014 as 
the comparison group. The follow-up periods were done according to the scheduled appointment 
date (mostly at 6 weeks and 6 months) from the date of operation, which ended on 30rd June 
2015. Statistical Package for Social Sciences (SPSS) software version 22.0 was used in the 
statistical analysis.  
 
 Results: Significant longer survivals were observed in FG group compared with 
conventional group (12 months versus 8 months), p<0.02.  Even without adjuvant therapies, 
HGG patients from FG group survived longer than those from conventional group (8.0 months 
versus 3 months), p = 0.006. No significant differences of postoperative Karnofsky performance 
scale (KPS) between groups at 6 weeks and 6 months after surgery. Multivariate analysis 
identified four independent predictors of survival: KPS>80 (p=0.01), histology (p<0.001), 
surgical method (p<0.001) and adjuvant therapy (p<0.001). Multiple logistic regression analysis 
showed only three predictors of survival: tumor located in non-eloquent or near eloquent area 
(p=0.092), surgical method (0.087) and adjuvant therapy (0.094). Although FG patients did not 
demonstrate significant influence of extent of surgical resection on patients’ survival and 
functional outcome, patients with GTR/ NTR appeared to survive longer than STR (10.0 months 
vs 8.0 months).    
 
 Conclusion: This study showed a significant clinical benefit for HGG patients in terms of 
overall survival using FG surgery without resulting in worsening of postoperative function 
outcome when compared with conventional surgical method.  However, the results might not be 
conclusive as this is a single centre study with small sample size. We advocate a further multi-
centered, randomized control trial to support these findings before FG surgery being 
implemented as a standard surgical treatment for all HGG patients in local practice.  
 
 
Dr Azmin Kass Rosman: Supervisor 
Dr Marymol Koshy: Co-supervisor 
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1. INTRODUCTION 
High grade gliomas (HGGs) are the most common and deadly adult primary intrinsic brain 
tumors that account about for about 2% of all cancers (Louis et al., 2007; Kohler et al., 
2011). In the US, the annual incidence is about 5/100,000 individuals with a peak incidence 
being in the fifth and sixth decades of life (Dolecek et al., 2012). Estimated number of new 
cases using the world standard population of primary malignant central nervous system 
tumor in 2008, was 3.8 per 100,000 in males and 3.1 per 100,000 in females (Ferlay et al., 
2010).   
 
National Cancer Registry (NCR) recorded 471 cases of brain, nervous system cancer in 
Peninsular Malaysia in 2007. The age standardized incidence rate (ASR) was 2.3 and 1.9 
per 100,000 male and female respectively, based on the National Cancer Registry of 
Malaysia data (Zainal Ariffin and Nor Saleha, 2011). HGGs were the most common 
histological type  of primary brain tumor accounted for 34.6 % (262) of all nervous system 
tumors over the period between 2003 and 2005 (Chye et al., 2008). 
 
HGGs are more common among men compared to women (Wen and Kesari, 2008). The 
median age of patients at the time of diagnosis is 64 years in the case of glioblastoma 
multiforme (GBM) and 45years in the case of anaplastic gliomas (Dolecek et al., 2012). 
These tumors are characterized by their rapid proliferation, marked infiltration and dismal 
prognosis (Iacob and Dinca, 2009). They are associated with tremendous morbidity and 
eventually nearly all the patients will experience recurrence and die of disease progression.  
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HGGs account for about 60-75% of all gliomas. According to World Health Organization 
(WHO), HGG tumors are grade III and IV tumors. Grade III tumors are diffusely infiltrate 
neoplasms with marked proliferative potential, high cellularity, nuclear atypia and 
increased mitotic activity. The grade III tumors consist of anaplastic astrocytoma (AA), 
anaplastic oligodedroglioma (AO) and mixed anaplastic oligoastrocytoma (AOA). Besides 
nuclear atypia and high mitotic activity, the pathognomonic features of Grade IV GBM are 
microvascular proliferation and/ or necrosis (Louis et al., 2007).  
 
Currently, they are no prevention strategies for HGGs. The risk factors that may predispose 
to development of brain tumors include chemical carcinogens, infection, radiation or virus 
(Ohgaki and Kleihues, 2005).  However, only ionizing radiation exposure had been 
established to be the causal among the studied risk factors (Baritchii et al., 2015). Genetic 
syndrome, such as Li-Fraumi is also frequently associated with the development of HGG 
(Ohgaki and Kleihues, 2005). 
 
Clinical manifestations of HGGs are determined by several factors, including tumor size, 
rate of growth and location. Tumoral mass tends to compress the neural pathways and 
cause distortion of brain structures (Pang et al., 2007).  Patients can present with focal 
neurological symptoms that reflects the location of tumor within brain parenchymal or just 
symptoms of raised intracranial pressure (Yuile et al., 2006). In the late phase of one cohort 
of HGG patients, drowsiness, dysphagia, progressive neurological deficit and seizure are 
the most common symptoms. In nearly half of the patients, seizures occurred in their end-
of-life phase and more specifically in the week before dying in one-third of the patients 
(Sizoo et al., 2010).  
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One and two-year survival rates of high grade glioma patients are only 53.7% and 14.6% 
despite the understanding of several efforts on surgical technique, oncological therapies and 
molecular aspects of the tumor (Shinoda et al., 2001). Median survival for GBM 12 months 
and 22 months in AA despite combination of surgery, chemoradiation (Ahmed et al., 2014). 
Even there are ongoing trials, deaths can occur inevitably from either recurrent or the 
progression of disease.  
 
Understand the factors that contribute to patients’ prognosis is important to direct 
subsequent treatment strategies  Specific tumor characteristic, clinical  and therapeutic 
factors that influence survival of HGG patients has been studied. Studies consistently 
identified that age, functional status, tumor grade and extent of tumor resection are among 
the significant prognostic factors influencing survival (Buckner, 2003; Laws et al., 2003). 
However, sex and tumor location were not an independent prognostic factor for 
progression-free survival (Ahmadloo et al., 2013).  
 
Among factors affecting patient’s outcome, the extent of surgical removal has been proved 
to have a great impact (Sanai et al., 2011; Stummer et al., 2011b). A retrospective study 
showed that extended resection significantly prolonged both progression-free survival and 
overall survival (Keles et al., 2006; De Bonis et al., 2013). Increasing extent of resection 
was associated with improved survival independent of age, degree of disability, WHO 
grade or subsequent treatment modalities (McGirt et al., 2009a).  
 
In a multivariate analysis, resection greater than 98% in HGG patients was significantly 
associated with improved survival from 8.8 to 13.4 months (Lacroix et al., 2001) . Sanai et 
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al demonstrated subtotal resection as low as 78% also correspond to a survival benefit and 
this trend continues even at the highest level of resection (Sanai et al., 2011).   
 
However, recently attention has also been paid to the influence of more extensive surgery 
on increase impairment of neurological function and reduces quality of life. The idea of 
completing excision without postoperative neurological deterioration remains a formidable 
challenge. McGirt et al found that extended resection heightens the risk of neurological 
deficit, which in turn leads to deterioration in quality of life (McGirt et al., 2009b).  
 
Several large series, however have demonstrated no difference in new postoperative deficit 
between patient undergoing gross total resection (GTR) vs subtotal resection (STR) 
(Stummer et al., 2008; McGirt et al., 2009a; Sanai et al., 2011). Brown et al showed 
improvement of overall quality of life at 2- and 4-month follow up in patients with gross 
total glioma resection (Brown et al., 2005). Ammirati et al also found that better 
neurological performance scores with an improvement of mean score of 6.8 in the 
completely resected group (Ammirati et al., 1987).  
 
Tumor recurrence typically occurs close to the resection bed, where there is an increased 
tumor cell density along the tumor margin (Pang et al., 2007). Tumoral cells at the 
periphery of the tumor are more migratory and resistant to apoptosis, thus contributes to 
treatment resistance and relapse. Beyond the periphery, there is a sharp fall off in cell 
numbers as the distance from the resection cavity increases (Giese et al., 2003). It is 
therefore hypothesized that local recurrence arises from resectable tumor left behind 
following an operation (Liang et al., 1991). Aggressive resection thus would help prolong 
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progression free and overall survival by decreasing tumor burden and possibly increasing 
adjuvant therapy efficacy (Stummer et al., 2011b).  
 
Management of HGG remains very challenging and difficult as none are curative. Ongoing 
clinical trials include focusing on understanding the molecular mechanism and gene 
mutation aim to provide a promising individual approach. The best currently available 
multimodal treatment approaches of HGGs include surgical excision to the extent feasible, 
followed by external-beam radiation and concomitant temozolamide (TMZ) chemotherapy 
followed by an additional 6 cycle of TMZ administration (Stupp et al., 2009).  
 
A trial by the European Organization for Research and Treatment of Cancer (EORTC) 
showed that overall survival was 2 months higher with concomitant adjuvant 
radiochemotherapy followed by adjuvant temozolamide than with radiotherapy alone 
(Stupp et al., 2005). More aggressive resection eliminates more tumor cells and thereby 
enhances the efficacy of subsequent adjuvant therapies. (Sanai and Berger, 2008; Stummer 
et al., 2011b).  
 
Based on National Comprehensive Cancer Network (NCCN) guidelines 2015, standard 
treatment of HGGs includes microsurgery resection followed by radio-chemotherapy 
(National Comprehensive Cancer Network) .  Unfortunately, resection of HGGs is limited 
by the difficulty in discerning marginal, enhancing tumor intra-operatively. The invasive 
and infiltrative nature of HGGs often makes complete resection difficult (Jovcevska et al., 
2013). Achieving complete resection is challenging under conventional white light 
microsurgical techniques and only achieved in 23% to 36% of all HGG patients. Thus, 
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continuous refinements of surgical approaches and techniques, thus are investigated. 
Techniques that optimize intraoperative tumor identification and resection are needed. 
 
Recently, 5-aminolevulinic acid (5-ALA), also known as Gliolan has emerged as a new 
surgical adjuvant used to identify glioma tissue under blue light. Introduction of this 
fluorescence-guided surgery in the mid 1990 provide an advanced method to visualize 
tumor at the cellular level. 5-ALA is a natural biochemical precursor that elicits synthesis 
and accumulation of fluorescent protoporphyrin in all epithelial and cancerous tissues. The 
concentration of fluorophore protoporphyrin IX (PPIX) is elevated in neoplastic cells, such 
as HGGs due to deficiency of ferrochelatase enzyme. Intra-operatively, under white light, 
no fluorescence is visible while shifting at violet-blue illumination tumor tissues appear 
red-light fluorescence (Puppa et al., 2014). 
 
The strongest evidence of extent of resection (EOR) improving outcome in HGGs comes 
from a randomized phase 3 trial of 5-ALA published in 2006 by the ALA-Glioma group 
study (Stummer et al., 2006).   The patient undergoes fluorescence-guided surgery had 
showed a 29% increase in the complete resection rate as opposed to the white light group. 
The 5-ALA group also had a higher 6-month progression free survival than the white light 
group (41% vs 21%) (Stummer et al., 2006). Gross total resection was also achieved in 
64% of the surgeries with preservation of all functional area and fiber tract (Feigl et al., 
2010).  
 
Postoperative early Magnetic resonance imaging (MRI) is the only method of objectively 
assessing the extent of resection. It is recommended that MRI should be performed in the 
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first 3 days after surgery before non-neoplastic contrast enhancement due to surgical 
manipulation becomes radiologically apparent (Albert et al., 1994). Determination of the 
amount of residual tumor is important to determine prognosis, direct further therapy and 
assess the response to therapy (Forsyth et al., 1997). However, surgical outcome 
assessment via postoperative MRI is not a common practice procedure due to the limited 
MRI facility in Malaysia. 
 
Albert, et al demonstrated that the opinion of the surgeon at the time of surgery is 
remarkably unreliable, with only a 30% correlation with MRI(Albert et al., 1994) . 
Therefore, MRI postoperatively is urgently needed to assess the extent ad success of 
surgery. Keles et al in 2006 found that the amount of residual tumor correlated with time to 
progression and overall survival with the most significant cutoff residual tumor volume was 
10cm3 (Keles et al., 2006). A great association between survival and recurrence with 
residual volume (RV) of 5cm3 is proven in a recent study (Chaichana et al., 2013).  
 
As shown in previous studies, the decrease in tumor mass is directly proportionate to the 
increase in effectiveness of combined adjuvant radio-chemotherapy (Stupp et al., 2009). 
Evidence shows that increased radicality in tumor resection without incurring postoperative 
neurological deterioration has a positive impact on survival as well as maintaining a better 
quality of life (Vecht et al., 1990; Stummer et al., 2011a).  
 
Despite the therapeutic strategies to treat HGGs are evolving rapidly, Malaysia still failed 
to demonstrate the expected standard HGGs management according to National 
Comprehensive Cancer Network Guideline. Department of Neurosurgery, Hospital Sungai 
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Buloh has adopted the new surgical adjunct, 5-ALA as the first public centre in Malaysia 
since 2010. This study investigated the effect of FG tumor resection using 5-ALA on 
patients overall survival and functional outcome as compared to conventional method. We 
also analyzed the significant predictors of survival in HGG patients. This study is done with 
the aim, to further establish the hypothesis that FG surgery does improve patient survival 
without causing worsening neurological deficit. We hope that this surgical method can be 
introduced to other public hospital in Malaysia and therefore improve patients’ overall 
survival. 
 
In Malaysia, due to the limitation of MRI facility, although postoperative plain computed 
tomography (CT) brain is not a standard imaging tool, it was routinely performed after 
surgery. The aim was to ensure no bleeding in the area of interest that warranted immediate 
intervention. The study highlights the importance of early postoperative MRI within 72 
hours as a standard imaging tool as stated in NCCN guideline 2015. It helps to assess the 
extent of tumor resection,   determine the prognosis of HGG patients and direct further 
therapy.  
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2. LITHERATURE REVIEW 
 
2.1 CLASSIFICATION OF GLIOMA  
Gliomas represent a group of low-grade and high grade brain tumors that originate from 
glia (from the Greek for ‘glue’), the brain tissue that was traditionally viewed as providing 
support functions to neural cells such as nutrients, oxygen, mechanical support, guidance 
in development, immune functions and waste disposal (Van Meir et al., 2010). The glia 
supporting tissue includes astrocytes, oligodendrocyte or ependymal cells (Louis et al., 
2007).   
WHO classified the glial tumors into four prognostic grades based on the histological 
features: grade I (pilocystic astrocytoma), grade II (diffuse astrocytoma), grade III 
(anaplastic astrocytoma) and grade IV (glioblastoma multiforme) (Louis et al., 2007). 
Grade III and grade IV tumor are commonly referred to as high grade or malignant glioma. 
They have an intrinsic tendency to differentiate along the astrocytic lineage, become more 
malignant over time and can be viewed as a continuum along an axis of increasing 
malignancy (Louis et al., 2007) .  Histological features that affect the prognosis include 
cellularity, nuclear atypia, mitotic activity, necrosis and microvascular proliferation. 
WHO grade II tumors have nuclear atypia alone. Grade III actrocytomas will display 
mitotic activity with nuclear atypia, whereas GBMs show nuclear atypia, mitoses, 
microvascular proliferation and/ or necrosis (Louis et al., 2007).   
Secondary GBM develops from grade II or III astrocytomas, whereas primary or de novo 
GBM occur without prior history of less malignant lesion. Amplification and / or over 
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expression of the epidermal growth factor receptor and murine double minute 2 (MDM2) 
gene are important in the development of primary GBM. Early mutation of TP53, over 
expression platelet derived growth factor leads to the development of secondary GBM 
(Van Meir et al., 2010) .  
 
2.2 GENDER  
It is well known that men represent a higher proportion of HGG sufferers than women 
(Wen and Kesari, 2008; Ferlay et al., 2010). Study done by Casaetelli et al showed that no  
association was found between gender and overall survival (Casartelli et al., 2009). Chen 
et al in his study demonstrated that a significant correlation between female gender and 
overall survival on univariate analysis (Chen et al., 2015). The longer survival in female 
patients had better survival compared to male may be due to the presence of hormones or 
tumor suppressor genes on the X chromosome (Seki et al., 2002) . 
 
2.3  PRESENTATION 
HGGs produce symptoms by a combination of focal neurological deficits from 
compression and infiltration of the surrounding brain parenchymal and raised intracranial 
pressure. Thus, patients can present with a variety of symptoms, including headache, 
progressive sensorimotor neurologic deficits, cognitive changes or seizure (Wen and 
Kesari, 2008). Headache occurs in approximately 50% of HGG patients is usually diffuse 
but can be localized to the same side of the head (DeAngelis, 2001).  
Unlike slow growing glioma, seizures affect approximately 25-60% of patients with 
HGGs (Chaichana et al., 2009). Okumus et al found that seizure is a significant prognosis 
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factor for survival in uni- and multivariate analyses (Okumus et al., 2012). Surgical 
removal of tumors improves intracranial pressure condition and often reduces epileptic 
seizures. Tumor-related epilepsy affects patient’s quality of life significantly, causes 
cognitive deterioration and result in significant morbidity (Chaichana et al., 2009). 
 
2.4  FACTORS INFLUENCING OUTCOME 
Several potential prognostic factors were analyzed to establish their effect on overall 
survival rate in high grade glioma patients. Table 2.1 showed the significant prognostic 
factors that influencing survival in the reported studies.  
Table 2.1 Predictor factors of survival in patients with high grade glioma 
 
Study 
 
Patients  
Patient variables 
Age KPS Histology  Primary 
site  
Tumor 
size 
Extent 
of 
resection  
Radio-
therapy  
Chemo-
therapy  
Ahmadloo 
et al. 
(2013) 
233 Yes Yes NA NA Yes Yes Yes Yes 
Ekici et 
al. (2013) 
98 Yes Yes NA NA NA NA NA Yes 
Hilmani 
et al. 
(2014) 
89 Yes Yes NA NA NA NA Yes NA 
Lacroix et 
al. (2001) 
416 Yes Yes Yes NA NA Yes NA NA 
Li et al. 
(2009) 
116 Yes Yes NA Yes Yes Yes NA Yes 
Salminen 
et al. 
(1996) 
106 Yes  NA Yes  NA NA NA Yes NA 
Zinn et al. 
(2013) 
21,783 Yes NA NA NA NA Yes Yes NA 
 
2.4.1 AGE 
The median age of patients at the time of diagnosis is 64 years in the case of GBM and 
45years in the case of anaplastic gliomas (Dolecek et al., 2012). Age at diagnosis is 
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associated with survival in glioma patients (Lacroix et al., 2001; Ekici et al., 2013). 
Patient’s age is inversely proportional to the period of overall survival. There is 
significant evidence between patient’s younger age and longer survival times. (Casartelli 
et al., 2009). Aggressive therapies administered to older patients are less effective, 
whereby they prolong survival time younger patients (Helseth et al., 2010). Thus, 
mortality risk increases as the age increases.   
 
2.4.2 KPS 
Patient’s functional status is an overall accepted independent prognostic factor in HGG 
patients. Various scales for assessment of patient’s performance have been developed and 
scoring system developed by Karnofsky is frequently used in the literature to assess 
patient’s performance status (Schag et al., 1984) . Karnofsky Performance Scale (KPS) is 
a well documented prognostic factor for survival and patient with an elevated KPS score 
have more favorable results (Lacroix et al., 2001; Li et al., 2009).  Studies consistently 
demonstrated patients with a KPS score >70 have a better prognosis (Stark et al., 2010b; 
Ahmadloo et al., 2013) 
The preoperative function class was assessed at admission before surgery, and the 
postoperative function class was the performance status approximately 4-6 weeks after 
discharged. In the series of Vecht et al, no significant difference was found in the 
incidence of worsening neurological function following GTR compared to limited 
resection (Vecht et al., 1990). C. Abrudan et al however, found that a global improvement 
of neurological status was seen in >85% of the GTR patients (Abrudan et al.).  
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2.4.3 PRIMARY SITE  
Gliomas commonly found in the cerebral hemispheres. Li et al reported that frontal lobe 
involvement is a statistically significant marker of delayed progression of postoperative 
disease (Li et al., 2009). An early retrospective by Simpson, et al stated also the frontal 
lobe location offered a survival benefit (Simpson et al., 1993). The effect of extensive 
resection on survival may also be partially affected by the tumor location. Deep seated 
tumors are often times less resection and therefore more prone to poorer outcomes. 
 
2.4.4 FUNCTIONAL LOCALIZATION 
Preoperative tumor functional localization and surgical accessibility are important in 
determining the feasibility of tumor resection (McGirt et al., 2009b; Feigl et al., 2010). A 
functional grading system (Friedlein grading A/B) was proposed (Friedlein et al., 2015) . 
Friedlein A (FGA) was characterized by malignant glioma in a functionally silent area or 
near the functionally eloquent area (<8mm) whereas Friedlein B (FGB) was characterized 
by suspected malignant glioma in the functionally eloquent area.  
Another high grade glioma grading system according functional localization was 
proposed by Sawaya, et al (Sawaya et al., 1998). Sawaya I comprises a tumor that located 
in functionally silent areas of the brain (non-eloquent brain) such as frontal or temporal 
pole, right parieto-occipital lobe and cerebellar hemisphere. Sawaya II comprises a tumor 
that located adjacent to eloquent brain area such as near motor cortex, sensory cortex, 
calcarine fissure, speech center, corpus callosum, dentate nucleus and brainstem. Sawaya 
III comprises a tumor that located in functionally eloquent area such as motor or sensory 
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cortex, visual or speech center, internal capsule, basal ganglia, thalamus, hypothalamus, 
dentate nucleus and brainstem. 
 
2.4.5 LATERALITY  
Studies have shown the laterality of high grade glioma (dominant or non-dominant 
hemisphere) is not an independent predictor of survival or functional outcome (Polin et al., 
2005; Chen et al., 2015).  
  
2.4.6 HISTOLOGY 
Histopathological diagnoses indicated HGGs according to WHO standards. A recursive 
partitioning analysis of three Radiation Therapy Oncology Group trials showed that 
among patients less than 50 years of age, astrocytoma with anaplastic and atypical foci 
was associated with significantly improved survival compared with glioblastoma.  The 
tumor grade were consistently identified as an independent prognostic that influencing 
survival (Salminen et al., 1996; Lacroix et al., 2001). Presence of necrosis within the 
tumor is considered crucial, showing the aggressiveness of the cells and they outgrow the 
blood supply, regardless their angiogenic potential). According to the latest WHO 
classification, GBM can be divided into various subtypes. Primary GBMs, arise de novo 
and occur mostly in older age groups, with shorter survival time and more frequently 
compared to secondary GBMs that progress from astrocytoma of low grade (Louis et al., 
2007).  
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2.4.7 TUMOR VOLUME 
Li et al revealed that tumor maximal diameter (TMD) was a significant factor related to 
overall survival in the univariate analysis (Li et al., 2009; Ahmadloo et al., 2013) . 
Amirjamshidi et al in his study demonstrated that patients with more voluminous tumor 
masses had the worst prognosis in univariate analysis (p<0.007), but lost its power in the 
final analysis.  (Amirjamshidi et al., 2010). 
 
2.4.8 EXTENT OF RESECTION  
Traditionally, surgical resection has been considered an option for relatively few patients 
with HGGs due to poorly defined borders of these infiltrative lesions. Besides achieving 
cytoreduction, tumor resection relieved symptoms of the patient and provides a conclusive 
pathologic diagnosis.   
Recent studies have documented the importance of surgical resection as one of the 
important independent predictors of survival (McGirt et al., 2009a; Stupp et al., 2009). 
Thus, the aim of surgery is to maximize the extent of tumor resection while minimizing 
the surgical insult to the normal, viable brain parenchymal.   
However, there is no consensus regarding the definition of complete tumor resection in 
the literature. Many author used the term of ‘complete’ (Stummer et al., 2008), ‘gross 
total’(Hardesty and Sanai, 2012) or ‘more than 98% tumor’ resection (Lacroix et al., 2001) 
according to post-surgical residual. Extent of excision was defined as gross total (>98% of 
the tumor removed), near total (>90% of the tumor removed), subtotal (<90% of the 
tumor removed) (Gulati et al., 2011).  
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It is now level 2b (Oxford centre for evidence-based medicine) showing that gross total 
resection (GTR) provides a significant survival advantage as compared to incomplete 
resection of contrast-enhancing tumor (Stummer et al., 2008). A complete resection of all 
gadolinium enhancing tumor significantly improves the survival effect of adjuvant 
therapy and chemotherapy (Stupp et al., 2009). There is now class II evidence confirming 
the value of maximal cytoreductive surgery and synergistic effect between aggressive 
surgery and chemoradiation.  
GTR also has been associated with several other benefits. By increasing the amount of 
tissue available for pathologic examination, GTR may help to improve diagnostic 
accuracy. It helps to improve seizure control and make it possible to administer local 
therapies like BCNU wafers. Patients are likely to require less steroid treatment, which 
reduces the risk of several steroid-related adverse events, including cushingoid habitus, 
steroid myopathy, peripheral edema and hyperglycemia (Olivi et al., 2010).  
 
2.4.9 RADIOTHERAPY 
Postoperative adjuvant radiotherapy had been of key importance to the treatment of HGGs 
for decades. External beam radian treatment (XRT) is usually recommended to start 
within 2-4 weeks following surgical resection.  The patients received a median dose of 
54Gy (range 40-60) Gy, delivered 5 days per week in fractions of 1.8-2.0Gy with a 
curative intent (Ahmadloo et al., 2013) 
The addition of radiotherapy to surgery increases survival among patient with GBM 
ranged from 3 months to a range of 7-12 months (Stupp et al., 2005). Besides, it was also 
obvious that radiotherapy without surgery resulted in consistently better survival than 
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those who were treated by surgery alone (Zinn et al., 2013; Hilmani et al., 2014).  This 
great clinical significance, especially benefits the elderly or patient with surgical 
contraindication.  
 
2.4.10 CHEMOTHERAPY 
Chemotherapy is assuming an increasingly important role in the treatment of HGGs.  
Before 1999, nitrosourea-based agents (carmustine and lomustine) were the most 
commonly used adjuvant chemotherapeutic agent in HGG patients (Adamson et al., 2009). 
However, patients did not show any improvement in term of response rate and overall 
survival.  
Temozolamide (TMZ) is an orally available, imidazotetrazine-derived second-generation, 
methylating agent with simple, well tolerated and a favorable toxicity profile. It readily 
crosses blood-brain barrier to achieve a cerebrospinal fluid concentration that is 
approximately 40% of plasma.  The most common adverse effect is hematologic toxicity 
(leucopenia and thrombocytopenia) (Mutter and Stupp, 2006).   
This chemotherapeutic agent was administered concurrently with radiotherapy with a dose 
of 75mg/m2 daily throughout the radiation course followed by 4-6 cycles of adjuvant 
temozolamide with a dose of 150-200mg/m2 daily for 5 days, every 4 weeks (Ahmadloo 
et al., 2013) 
 In a Phase III randomized study (EORTC 26981/22981-NCIC CE3), concomitant 
administration of temozolamide with radiotherapy increased median overall survival to 
14.6 months compared with 12.1 months for radiotherapy alone (Stupp et al., 2005). The 
 
 
18 
 
study also showed improvement in the 2-year survival rate from 10% to 26% (Stupp et al., 
2005). The overall survival in the TMZ arm was 9.8% in a 5-year analysis of the EORTC-
NCIC trial that was published in 2009 (Stupp et al., 2009).  Therefore, TMZ administered 
concurrently during and after XRT has become a new standard-of-care treatment.  
 
2.5 NEUROIMAGING  
MRI with contrast is the most sensitive and specific study. CT may miss small tumors that 
are not enhanced with contrast agent. Anaplastic astrocytoma usually exhibit hypointense 
T1 and hyperintense T2-weighted signal abnormality that may include various degrees of 
contrast enhancement and edema. Whereas, GBM shows a typically heterogeneously 
irregular ring-nodular enhancing mass with central necrosis and surrounding vasogenic 
edema (Sathornsumetee et al., 2007). Differential diagnoses for HGG include abscess, 
metastasis or primary CNS lymphoma (Behin et al., 2003). 
Contrast enhancement on  MRI due to extravasation from tumor vasculature that lacks of 
endothelial tight junction of which is a well-known characteristic of HGGs (Scott et al., 
2002).  Wong et al shows that higher maximum gadolinium uptake rate were associated 
with shorter survival in evaluating HGG (Wong et al., 1998).  GBM frequently has central 
necrosis and more extensive peritumoral edema than that associated with anaplastic 
astrocytoma.   Absence of necrosis on imaging studies is an important prognostically 
favorable variable. A low density necrotic area within glioma is believed to indicate rapid 
growth and malignant behavior (Lacroix et al., 2001). 
CT immediate postoperative was obtained from each patient to diagnose asymptomatic 
complication that might be related to surgery. The extent of surgical resection was 
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determined by neuroradiologist through T1MRI images with contrast, which were 
obtained during the first 72hours postoperatively. Early postoperative MRI can determine 
the amount of residual tumor and also detect the surgical complication as early as possible. 
Besides, it is to avoid confounding the interpretation of images by postoperative 
inflammation and disruption of blood brain barrier (Albert et al., 1994). Thereafter, MRI 
was performed at 6 months to look for evidence of radiological progression.  
 
2.6 CONVENTIONAL RESECTION  
Surgery has become the cornerstone in the initial management of HGGs. Besides 
establishing a histopathological diagnosis, the aim of surgery is to maximize tumor 
resection while sparing the normal functioning brain parenchymal. Conventional 
neurosurgical technologies for tumor resection involve the use to image guided system 
that provides an intraoperative guidance to the surgeon. The system was designed as such 
by using the pre-operative MR image, relates the location of surgical tools that tracked 
intraoperatively to the preoperative images and guides the surgeon throughout the 
patient’s anatomy. 
However, intraoperative brain shift and deformation after CSF drainage and bone removal 
had resulted in the inaccuracy of the image-guided system. The wisest approach for 
determining the completeness of HGG resection surgery is based entirely on the judgment 
of the surgeon. Clues such as tissue texture and discoloration, bleeding and vascularity of 
resection planes, and proximity to anatomic landmarks are used to judge the completeness 
of resection. The subjective nature of judging tumor margins based on gross cues yields a 
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highly inconsistent surgical outcome. Even in the experienced hands, the rate for complete 
resection of HGGs under white light vary between 13-20% (Albert et al., 1994). 
 
2.7 FLOURESCENCE-GUIDED SURGERY 
 
2.7.1 General knowledge  
5-aminolevulinic acid (5-ALA) is a natural biochemical precursor for the synthesis of 
heme in all mammalian cells (von Campe et al., 2012). Both ALA and protoporphyrin IX 
(PpIX) are naturally present in the human body. As shown in Figure 2.1, ALA is formed 
in the mitochondrion from glycine and succinyl coenzyme A from Kreb cycle by the 
activity of enzyme ALA syhthase (ALAS). ALA then diffuses into cytosol and undergoes 
enzymatic modification through intermediate porphyrin before transported by adenosine 
nucleotide transporter back to the mitochondrion. The coproporphhyrinogen oxidase then 
act on the pprotoporphyrin towards heme production and inducing the synthesis of 
endogenous fluorescence molecule, protoporphyrin IX (PpIX) in the mitochondrion(Teng 
et al., 2013). Ferrochelatase is responsible for converting the PpIX into non-fluorescent 
molecule, heme (Colditz et al., 2012). 
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Figure 2.1: Porphyrin-heme biosynthetic pathway and putative mitochondrial transporters  
 
There is a deficiency of ferrochelatase enzyme in neoplastic cells, such as those in HGGs. 
There is also association between high 5-ALA level and increased nitric oxide level via 
nitric oxide synthetase 2 upregulation. (Nokes et al., 2013). Exogenous 5-ALA 
administration thus leads to increasing concentration of PpIX. Also the higher 5-ALA 
uptake by tumor cells can be due to disruption of blood brain barrier, increased 
neovascularization and overexpression of membrane transporter. (Hadjipanayis et al., 
2011). Accumulation of fluorophore PpIX in tumor cells will exhibit red-light 
fluorescence under blue light that looked relatively normal with white light. 
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2.7.2 Mechanism of action 
5-ALA as drinking solution is rapidly and completely absorbed. After oral administration, 
PpIX plasma levels peaks at 2-6 hours, disappears by 12 hours and normal PpIX level is 
reached after 24hours (Teng et al., 2013). It had a terminal half-life of 1-3 hours and 
excretion of PpIX is via hepatic metabolism and approximately 30% of administrated 5-
ALA excreted unchanged in urine within 24 hours (Teng et al., 2013). Thus, exposure of 
eye and skin to strong light sources (direct sunlight or brightly focused indoor light) 
should be avoided for 24 hours after administration of 5-ALA to prevent occurrence of 
photosensitivity (Colditz et al., 2012).  
 
2.7.3 Contraindication and side effect  
Administrated of antacid, however should be avoided because the dye is easily 
decomposes in the presence of alkali. The drug should not be administered with other 
phototoxic substances such as tetracycline, sulfonamide or fluoroquinolones (Colditz et 
al., 2012).  The use of 5-ALA is also contraindicated in the case of porphyria, a genetic 
disease (Teng et al., 2013). No trials have been performed in patients with clinically 
relevant hepatic or renal impairment and the safety and efficacy of 5-ALA in children 
have not yet been established. The most serious side effects include anemia, 
thrombocytopenia, leukocytosis, neurological disorders and thromboembolism especially 
when higher doses (>40g/kg body weight) are used (Panciani et al., 2012).  
 
2.7.4 5-ALA and clinical usage 
The first paper detailing the use of 5-ALA for photodynamic diagnostic was in 
1797(Malik and Djaldetti, 1979). Thereafter, clinical usage of 5-ALA was applied in 
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tumor originating in the epidermis, oral mucosa, bile ducts, urothelium, bronchi and 
others (D’HALLEWIN et al., 2000; Guyon et al., 2012). In 1998, it was approved by the 
Food and Drug administration (FDA) as a therapeutic drug for solar keratosis (Gold and 
Goldman, 2004).  
 
2.7.5 5-ALA and Neurosurgery 
Following the positive result of the phase III trial, 5-ALA has been granted by the 
European Medicines Evaluation Agency for the use in the European community in adult 
patients during surgery for HGG and named Gliolan.  Patients were then treated according 
to the published protocol (Stummer et al., 2006). The neurosurgeon is required to 
complete a certified FG surgery course before using Gliolan (Colditz et al., 2012). 
A 20mg/kg body weight of 5-ALA was administered orally in the presence of medical 
personnel 2-4 hours before induction of anesthesia. The solution was prepared by 
dissolving the content of one vial (1.5g) in 50ml of drinking water.  
The patient was put on 4mg dexamethasone three times per day before the operation. All 
HGGs resections were done by consultant trained in the use of 5-ALA by using a 
microscope which enables switching from conventional white xenon illumination to 
violet-blue excitation light. PpIX will emit red light in the visible spectrum at 635 nm 
with a smaller peak at 704 nm to produce fluorescence after excited by blue light at a 
wavelength of 375 - 440 nm (Ishihara et al., 2007). The operative microscope with a long 
pass filter only permits the passage of light greater than 440 nm. This then enable the 
surgeon to resect the red-violet tumor tissue in a gross total fashion.  
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Different fluorescent qualities were observed correlated to the tumor burden and WHO 
grades in HGG patients (Hefti et al., 2010; Díez Valle et al., 2011; Roberts et al., 2011). 
Two types of fluorescence that were encountered during surgery include solid and vague 
fluorescence. According to Hefti et al, solid fluorescence indicates viable tumor tissue and 
thus appeared deep red, whereas vague fluorescence is the pink fluorescence that 
encountered between solid tumor and non-fluorescence blue brain tissue (Hefti et al., 
2010).  Intraoperative fluorescence therefore is subjective and is mainly based on the 
judgment of the surgeon. Panciani et al found that the sensitivity of 5-ALA surgery was 
91.1% with the documented specificity of 89.4% (Panciani et al., 2012).  
 
2.8 OVERALL SURVIVAL 
Date of surgery was considered at the time of diagnosis. Overall survival was measured 
from the date of surgery to the date of death due to any cause, to the date of withdrawing 
from the study and to the final analysis. As an overall survival reflects a clinically 
meaningful benefit that can be objectively assessed, thus it is usually considered as the 
definitive end point for HGG patients.  
A prospective clinical trial evaluating the utility of fluorescence-guided high grade glioma 
resection demonstrated a 4.9-month improvement in survival in patient undergoing 
complete excision compared to those with subtotal resection (Stummer et al., 2011a). 
Whereas, the best adjuvant chemotherapeutic regimen for GBM improves survival 2.5 
months (Stupp et al., 2005).  
 
 
